中国药房2012，Vol.23Issue(28)：2627-2629,3.DOI:10.6039/j.issn.1001-0408.2012.28.12
头孢噻肟钠与环丙沙星预防生殖内分泌科围手术期感染的最小成本分析
Cost-minimization Analysis of Cefotaxime Sodium vs.Ciprofloxacin for Preventing Infection in Perioperative Period in the Department of Reproductive Endocrinology
摘要
Abstract
OBJECTIVE: To evaluate the pharmacoeconomic effectiveness of cefotaxime sodium vs. ciprofloxacin for preventing infection in perioperative period in the department of reproductive endocrinology. METHODS: 240 cases of patient from July 2009 to January 2010 who met the selection criterias were selected in the department of reproductive endocrinology in our hospital. They were randomly divided into the treatment group (cefotaxime sodium) and the control group (ciprofloxacin) as 1:1. Patients were administed as Clinical guidelines for antibiotics. The curative effects and adverse events were monitored and the cost-minimization analysis was conducted. RESULTS: In control group, 2 cases of urinary tract infection. In the treatment group, 1 cases of urinary tract infection, 1 case of respiratory tract infection, 1 case of infection of unknown causes, and there was no statistical difference between the 2 groups (P>0.05). In control group, the drug cost, non-drug cost, time cost and total coat were (837.75 ± 259.18), (6 145.0011 068.20), (215.50±60.66), (7 183.10 ± 1 182.80) yuan; In the treatment group, they were(845.97 ± 182.41), (6 183.40 ± 1 026.70), (204.19 ± 56.65), (7 233.60 ± 1 108.30) yuan. There was no statistical difference between 2 groups (P>0.05). CONCLUSION: There was no statistical difference between cefotaxime and ciprofloxacin for preventing infection in perioperative period in the department of reproductive endocrinology about the pbarmacoeconoic. Due to the high resistance rates of quinolone, we recommended cefotaxime sodium.关键词
头孢噻肟钠/环丙沙星/围手术期/预防感染/最小成本分析Key words
Cefotaxime sodium/ Ciprofloxacin/ Perioperative period/ Prevent infection/ Cost-minimization analysis分类
医药卫生引用本文复制引用
郭远超,徐克惠,张伶俐..头孢噻肟钠与环丙沙星预防生殖内分泌科围手术期感染的最小成本分析[J].中国药房,2012,23(28):2627-2629,3.基金项目
四川省卫生厅科研资助项目(090265) （090265）
